Mazor Robotics Announces Key European Patent for Renaissance Surgical Guidance Robot
CAESAREA, Israel--(BUSINESS WIRE)--Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced that the European Patent Office granted European Patent No. 1414362 entitled "Miniature Bone-mounted Surgical Robot," which covers the Companys flagship product, Renaissance™. Renaissance is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner.The newly granted patent includes claims for surgical robots, including Renaissance, to be mounted to a patients spine. This maximizes the likelihood of accurate positioning of implants during surgical procedures even if patient movement occurs.
"This patent is an important new addition to our global intellectual property portfolio and increases the value of our spine franchise," said Ori Hadomi, President & CEO of Mazor Robotics. "We believe this patent secures our unique surgical approach, as Mazor Robotics technology is the only system which is fixated to the patients anatomy, assuring the highest accuracy levels and reliability in spine surgeries which would be almost impossible to emulate otherwise."
Mazor holds related patents in other major markets throughout the world. The company has a solid IP position in global markets, including the US, Canada and Europe, protecting all of its core technology and applications.
Mazor Robotics is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and OR staff. Mazor Robotics flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 12,000 implants in the USA and Europe. Multiple peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. The Company received authorization to affix a CE Mark for the Renaissance system in Europe for brain surgeries in May 2011. For more information, please visit www.mazorrobotics.com.
Posted by Sean Fenske, Editor-in-Chief, MDT